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Abstract
There is increasing interest in the use of adjuvant hor-
monal therapies, which are given after the resection or
destruction of all gross disease, in early-stage prostate
cancer, as a significant proportion of patients experience
progression and/or die from the disease despite under-
going therapy with curative intent. Several retrospective
studies suggest that adjuvant hormonal therapy may
improve long-term outcome after radical surgery in men
with positive lymph nodes, although this approach has
yet to be studied in a prospective setting. No studies of
adjuvant therapy for patients with extracapsular exten-
sion at surgery have been completed, but in an interim
analysis of an open controlled trial, adjuvant flutamide
significantly improved progression-free survival at 4
years. Three prospective studies in the radiotherapy set-
ting have shown that adjuvant luteinizing hormone-
releasing hormone (LH-RH) agonist therapy significantly
improves progression-free and/or overall survival. Fu-
ture studies need to define patient subgroups who will
benefit most from adjuvant therapy. The side effects of
the different therapeutic options also need to be com-
pared. It is hoped that many of the outstanding questions
concerning adjuvant hormonal therapy will be answered
by the ongoing Bicalutamide Early Prostate Cancer Pro-
gramme.
Introduction
The most appropriate approach to the management of
early prostate cancer, that is disease limited to the pros-
tate and draining lymph nodes, has yet to be defined.
Conventionally, patients with early-stage disease have
been treated by radical prostatectomy, radiotherapy or
watchful waiting; the latter practice is particularly com-
mon in Scandinavia, whereas a very high proportion of
patients in North America undergo radical surgery. In
recent years, we have seen the introduction of endocrine
therapy, medical or surgical castration and/or antiandro-
gen therapy at earlier disease stages than before [1]. In
particular, there is now considerable interest in the use of
adjuvant hormonal therapy, an additional treatment giv-
en after resection or destruction of all gross disease which
is hoped to improve outcome, particularly survival out-
come. This paper will discuss the current status of adju-
vant hormonal therapies including orchiectomy, luteiniz-
ing hormone-releasing hormone (LH-RH) agonists and
non-steroidal antiandrogens in both the surgical and ra-
diotherapy settings.
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Adjuvant Hormonal Therapy after Radical
Prostatectomy
Why Use Adjuvant Therapy after Radical
Prostatectomy?
It is now well recognized that a significant proportion
of men with early-stage prostate cancer experience local or
systemic progression and/or die from the disease despite
receiving therapies of primary curative intent and that
this risk rises with increasing pathological stage [1]. For
example, in a study of 721 men with clinically localized
T1 or T2 (cT1–2) disease [2], the most favourable out-
come at 10 years with respect to progression (defined as
an elevated postoperative prostate-specific antigen [PSA]
10.2 ng/ml, evidence of local recurrence or distant metas-
tases) was seen in men with organ-confined disease, who
had an 84.7% probability of remaining progression-free.
This was significantly (p ^ 0.0001) better than in men
with either focal or established capsular penetration (but
negative seminal vesicles and negative lymph nodes) in
whom the progression-free risk was 67.7 and 58.4%,
respectively. For men with negative seminal vesicles and
negative lymph nodes (n = 617), the presence of positive
surgical margins also influenced the risk of progression,
with a 10-year progression-free risk of 54.9% compared
with 79.4% in those with negative margins (p ! 0.00001).
The prognosis was particularly poor in men with seminal
vesicle invasion or lymph node metastases. Of the former
group, only 27% were free of disease at 10 years, whereas
all patients with lymph node metastases had progressed
within 10 years.
Similarly, Iselin and coworkers [3] have recently re-
ported that the incidence of PSA failure (defined as a PSA
10.5 ng/ml) 5 years after radical perineal prostatectomy
in 1,242 men with cT1–2N0M0 disease increased with
increasing pathological stage (organ-confined disease 8%,
specimen-confined disease 35%, positive surgical margins
65%; p = 0.001). Patients with organ-confined disease
continued to have an excellent disease-free survival at
8 years.
Radical surgery is, therefore, not curative in many
patients with early-stage disease. However, the use of
neoadjuvant therapy does not appear to offer any addi-
tional benefit in this setting, even in patients with cT2a–
T2b disease, probably due to residual foci of cancerous
cells outside the surgical margin [4]. Adjuvant therapy
may, nevertheless, have a role, although not all patients
can be expected to benefit; for example, given the gener-
ally favourable prognosis for organ-confined disease, it is
probably unreasonable to administer a treatment which
may have a negative impact on quality of life to all of
these men. The challenge, therefore, is to identify those
subgroups for whom adjuvant therapy may be beneficial.
There are numerous studies describing prognostic fac-
tors for disease recurrence after radical prostatectomy,
which may be of value in selecting those patients most
likely to benefit from adjuvant therapy. These prognostic
factors include the Gleason score, extent of capsular pene-
tration, status of the surgical margins, seminal vesicle
involvement and lymph node metastases [2, 3]. In partic-
ular, adjuvant therapy may be beneficial for patients who
are found to have lymph node metastases or pT3 disease
at surgery. In this latter group, the 10-year disease-free
survival is approximately 50% [1].
Adjuvant Therapy in Men with Lymph Node
Metastases
The role of radical prostatectomy in patients who
present with lymph node metastases is controversial.
However, in a retrospective matched-pair comparison of
radical prostatectomy with pelvic lymphadenectomy plus
early orchiectomy and orchiectomy alone, Ghavamian
and coworkers [5] showed that the removal of the prostate
increased the chance of survival at 10 years; the combined
approach improved both the 10-year tumour-specific sur-
vival (79 vs. 39%; hazard ratio [HR] 0.28; 95% confi-
dence intervals [CI] 0.13–0.59; p ! 0.001) and overall
survival (66 vs. 28%; HR 0.36; 95% CI 0.20–0.66;
p ! 0.001) compared with orchiectomy alone. However,
when matching included the preoperative PSA level, radi-
cal prostatectomy plus orchiectomy conferred a much
smaller survival advantage, with a 5-year cause-specific
survival of 79% compared with 63% with orchiectomy
alone (HR 0.42; 95% CI 0.08–2.25; p = 0.19).
The Mayo Clinic has administered early adjuvant hor-
monal therapy after radical prostatectomy in patients
with lymphatic spread for many years. In a retrospective
study, Zincke and coworkers [6] reported that the 10-year
probability of remaining free of progression (local or
distant recurrence) for men who had received adjuvant
hormonal therapy (orchiectomy and/or oral hormones
with or without radiation) was significantly superior to
that in men who underwent surgery alone with deferred
androgen deprivation (76.4 vs. 24.3%; p ! 0.0001). How-
ever, this did not translate into a statistically significant
survival advantage (p = 0.073) or to an increase in cancer-
specific survival (80.1 vs. 71.4%; p 1 0.1). In a further
retrospective study, the same group demonstrated that
patients with diploid tumours who received adjuvant hor-
monal therapy had a significantly better cause-specific
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Table 1. Side effects and discontinuation of therapy in a controlled
trial of adjuvant flutamide therapy after radical prostatectomy for
pT3 disease
Flutamide
(n = 139)
Control
(n = 144)
Gynaecomastia 29 (20.8%) –
Hepatic toxicity 4 (2.9%) –
Nausea/vomiting 10 (7.2%) 2 (1.4%)
Discontinuation due to side effects 28 (20.1%) 1 (0.7%)
survival at 15 years than patients who did not (83.2 vs.
48.5%; p ! 0.002); no impact on survival was apparent
before 10 years [7].
The results of these and other retrospective studies [8]
suggest that combining radical prostatectomy and adju-
vant androgen deprivation may improve long-term out-
come in men with positive lymph nodes, as well as elimi-
nating the possibility of local problems from the primary
tumour. These results need confirming in a prospective
study with a randomized design.
Adjuvant Therapy in Stage pT3 Disease
No studies of adjuvant therapy for patients with extra-
capsular extension at surgery have been completed. How-
ever, an interim analysis of an open, randomized con-
trolled trial of adjuvant flutamide 250 mg three times dai-
ly, in which progression was defined as PSA, local or sys-
temic failure, has shown that the antiandrogen signifi-
cantly improved the progression-free survival at 4 years
(90 vs. 69%; p = 0.0029) [9]. However, when patients in
whom the only indicator of progression was an increase in
PSA are excluded, the proportion of men with progression
is low and similar in the two groups (flutamide 4/139, con-
trol 5/144).
The incidence of study withdrawal due to side effects
in the flutamide group was disappointing, with 28/139
(20.1%) men discontinuing therapy (table 1). The pre-
dominant side effects were gynaecomastia (20.8%), nau-
sea/vomiting (7.2%) and hepatic toxicity (2.9%); corre-
sponding rates of these events in the control arm were 0,
1.4 and 0%, with only 1/144 (0.7%) withdrawing from the
study. Further follow-up of the patients in this study is
necessary to establish if adjuvant flutamide has a positive
benefit with respect to survival.
Adjuvant Hormonal Therapy after Radiotherapy
Why Use Adjuvant Therapy after Radiotherapy?
As in the surgical setting, outcome after radiotherapy
correlates with clinical stage. In clinically localized dis-
ease, the 5- and 10-year survival for men with cT1 disease
is about 75–85 and 55–80%, respectively; corresponding
survival rates for cT2 disease are 55–80 and 45–65% [1].
Patients with cT3–4 disease have a poorer outcome, with
a 5-year survival lower than 50%.
Radiotherapy and endocrine therapy may have an
additive effect on cancer cells and, therefore, the initia-
tion of adjuvant or neoadjuvant endocrine therapy may
improve the outcome after radiotherapy. In general, as
radiotherapy patients tend to have a higher clinical stage
than radical prostatectomy patients, adjuvant therapy is
expected to afford greater benefit after radiotherapy than
after radical prostatectomy. 
Prospective Studies of Adjuvant Therapy
To date, three prospective randomized studies have
evaluated the benefits of adjuvant hormonal therapy after
radiotherapy of curative intent [10–12].
The Radiation Therapy Oncology Group (RTOG) pro-
tocol 85-31 was designed to prospectively assess the effi-
cacy of an adjuvant LH-RH agonist after radiotherapy for
stage C or D1 disease [10]. A total of 977 men scheduled
for radiotherapy were enrolled in this study and random-
ized to either immediate hormonal therapy with goserelin
acetate 3.6 mg/month, which was commenced during the
last week of radiotherapy (n = 477), or to radiotherapy
only with hormonal therapy administered only at the time
of relapse (n = 468). The majority of enrolled patients
(85%) had a Gleason score 66. Just over 25% of patients
had positive lymph nodes; about 15% of men had pre-
viously undergone radical prostatectomy. Pretreatment
prognostic factors were well balanced between the two
groups.
Follow-up time in this study ranged from 0.23 to 8.82
years (median 4.5 years). Adjuvant therapy significantly
improved both the local progression rate at 5 years (16 vs.
29%) and the disease-free survival (60 vs. 44%) (both p !
0.0001). The analyses of disease-free survival, including
PSA failure (cut-off either 1.5 or 4 ng/ml), and of the
development of distant metastases also favoured the adju-
vant arm (all p ! 0.0001). Overall survival did not differ
significantly between the groups (75 vs. 71%; p = 0.52);
however, when patients were subdivided according to
Gleason score, adjuvant therapy did improve overall
5-year survival in the subgroup with a Gleason score of
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Fig. 1. Overall survival after adjuvant LH-RH agonist treatment fol-
lowing radiotherapy for stage C and D1 prostate cancer: subgroup
analysis, Gleason score 8–10 subgroup. Adapted with permission
[10].
Fig. 2. Overall survival in patients with pN0–3M0 prostate cancer
following radiotherapy with or without orchiectomy. Adapted with
permission [11].
8–10 (66 vs. 55%; p = 0.03) (fig. 1). When prostatectomy
patients were excluded from the analysis of patients with
a Gleason score 8–10, the difference in overall survival
between the adjuvant and control arms was even greater
(p = 0.01). Follow-up is continuing in this study to estab-
lish whether the improved local control and disease-free
survival seen in the adjuvant arm will ultimately prolong
survival in patients with a Gleason score of 2–7.
In a second study, Granfors and coworkers [11] evalu-
ated the impact of combined orchiectomy and external
radiotherapy compared with radiotherapy alone, with an-
drogen ablation given at relapse in men with T1–4NxM0
disease. The authors planned to enrol up to 400 men, but
they terminated the study after an interim analysis in 91
men (radiotherapy plus orchiectomy 45, radiotherapy
only 46), showing a high incidence of progression in the
radiotherapy arm. Of the men enrolled, 39 (43%) had
lymph node involvement.
After a median follow-up of 9.3 years (range 6.0–11.4
years), the mortality from any cause was 38% in the com-
bined treatment group and 61% in the radiotherapy group
(p = 0.02) (fig. 2). The advantage for adjuvant therapy
with respect to cause-specific mortality almost attained
statistical significance (27 vs. 44%; p = 0.06). The differ-
ence between the treatment groups in both the overall and
cause-specific mortality was mainly seen in men with pos-
itive lymph nodes (p ! 0.001 and p = 0.001, respectively).
Adjuvant therapy also reduced the proportion of patients
with local or distant failure (p = 0.005). However, when
patients were subdivided according to the presence or
absence of lymph node metastases, the benefits of adju-
vant therapy on time to progression were confined to the
subgroup with positive nodes.
The third prospective study of adjuvant therapy in the
radiotherapy setting was conducted by the European
Organization for Research and Treatment of Cancer
(EORTC) and was reported by Bolla and associates [12].
This study involved 415 men with previously untreated
prostate cancer without nodal involvement who were ran-
domized to receive external pelvic irradiation alone (n =
208) or with adjuvant goserelin acetate 3.6 mg/month
commenced immediately and continued for 3 years. Pa-
tients in this study had a poorer prognosis than those in
the two trials described above; 85% had T3–4 disease and
more than half had a pretreatment PSA 120 ng/ml.
With a median 45 months’ follow-up, the Kaplan-
Meier estimates for the 5-year overall survival were 79
and 62% in the adjuvant and control arms, respectively
(p = 0.001) (fig. 3); for overall survival the HR was 0.50
(95% CI 0.33–0.76). These results need to be considered
in the context of the lower than expected survival rate in
the control arm, which implies that the patients had
more advanced disease than stated [4]. Alternatively,
patients may have been inadequately staged or had an
unusually high rate of intercurrent deaths. For patients
who survived 5 years, the disease-free rate was 85 and
48%, respectively (p ! 0.001) (fig. 3). Adjuvant therapy
also improved local control (HR 0.19; 95% CI 0.10–0.37;
p ! 0.001). Treatment with an LH-RH agonist was not
associated with an increase in grade 3 or 4 adverse
events.
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Fig. 3. Disease-free and overall survival in men with locally ad-
vanced prostate cancer treated with radiotherapy with or without
hormonal deprivation (n = 401). Adapted with permission from
[12].
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The Bicalutamide Early Prostate Cancer
Programme
Non-steroidal antiandrogen therapy offers significant
quality of life benefits over castration, particularly with
respect to sexual activity, and is, therefore, of consider-
able interest as an adjunctive treatment in early prostate
cancer. In this context, therapy will be long-term and the
antiandrogen must be well tolerated; comparative data in
other settings show that bicalutamide has a better tolera-
bility profile than flutamide.
A large ongoing international programme is investigat-
ing the role of bicalutamide in early prostate cancer (T1–
4NxM0) [13]. The programme comprises three random-
ized studies in different geographical areas (North Ameri-
ca, Scandinavia and other areas, but predominantly Eu-
rope excluding Scandinavia), of similar design, in which
bicalutamide 150 mg/day will be compared with placebo
either as an adjuvant to therapy of primary curative intent
(radical prostatectomy or radiotherapy) or as immediate
hormonal therapy. Recruitment to the programme began
in 1995 and is now complete, with a total patient sample
of 8,113 [13]. Of the patients recruited in North America
(n = 3,292), more than 80% had undergone radical sur-
gery, compared with about 60% in the European study
(n = 3,603) and !20% in Scandinavia (n = 1,218). These
differences are an accurate reflection of routine clinical
practice in the different geographical areas. There was
also a difference between the geographical areas with
respect to tumour stage, with more than 70% of patients
in the North American trial having a tumour stage !T3
compared with about 60% in the other two studies. How-
ever, the randomization procedure has ensured that both
the treatment groups are well balanced with respect to
both demographic and prognostic characteristics [13]. It
is anticipated that the results of this study, which is the
largest ongoing prostate cancer trial in the world, will pro-
vide important information on the role of adjuvant an-
tiandrogen therapy in early prostate cancer.
Conclusions
In conclusion, adjuvant hormonal therapy appears
promising, particularly in the radiotherapy setting and
also in certain patient subgroups following radical prosta-
tectomy. However, many issues still need to be addressed.
The patient subgroups who will benefit most from adju-
vant therapy need to be defined. The long-term side
effects of the different therapeutic modalities available for
adjuvant therapy need to be compared as quality of life is
particularly important in men with early-stage disease.
Finally, it is important to demonstrate that adjuvant ther-
apy confers a survival benefit. It is hoped that the ongoing
bicalutamide early prostate cancer programme will an-
swer some of these outstanding issues.
Adjuvant Hormonal Therapy in Prostate
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Case Presentation
A 52-year-old academic was seen by an outpatient urologist in
February 1994, at which time no evidence of prostate cancer was
found; digital rectal examination (DRE) was normal and the pros-
tate-specific antigen (PSA) level was !4 ng/ml. Between February
and November 1994, the patient had a deterioration of voiding and
on repeat DRE, there was an apical induration suggestive of a cT2
tumour; PSA was 4.3 ng/ml. The patient underwent a prostate biopsy
and one of the two samples was positive for a G2 prostate cancer. A
bone scan in December 1994 was normal. A transrectal ultrasound
suggested the presence of a bilateral T3 tumour and, on this basis, the
patient underwent radical prostatectomy. Pathological findings were
a T3 tumour with three positive lymph nodes. Despite these findings,
the prostate was removed at the patient’s prior request. The postop-
erative course was free from complications. The patient was conti-
nent and 28 days after the operation he had a PSA of !0.25 ng/ml.
At the patient’s request, adjuvant maximum androgen depriva-
tion, with a LH-RH agonist, and flutamide was initiated. Subse-
quently, flutamide was withdrawn due to the occurrence of side
effects and bicalutamide was substituted. This treatment was contin-
ued for just less than 2 years and then the referring physician decided
to stop treatment. At 38 months PSA began to rise, reaching about
2 ng/ml in April 1999. No decision about further treatment has yet
been made.
Although many present would not have proceeded to remove the
patient’s prostate, it was generally felt that in the circumstances this
patient should not have been withdrawn from maximum androgen
deprivation therapy and that this therapy should be recommenced.
The possibility of intermittent therapy was also raised by a member
of the panel, but it was stressed that this approach remains experi-
mental.
